Loading...
MISX
RASP
Market cap1.51bUSD
Feb 09, Last price  
166.40RUB
1D
-0.51%
1Q
-0.30%
Jan 2017
108.76%
IPO
164.17%
Name

Raspadskaya PAO

Chart & Performance

D1W1MN
MISX:RASP chart
P/E
—
P/S
0.01
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-0.29%
Rev. gr., 5y
21.26%
Revenues
119.24b
-26.33%
19,263,315,59535,470,626,98414,978,064,00221,584,769,78223,227,056,10216,454,616,86517,935,744,94924,646,416,04530,786,188,41030,738,112,60050,057,672,84075,399,579,50061,748,295,00046,056,546,000156,450,420,000209,241,966,000185,823,000,000161,858,925,000119,238,000,000
Net income
-53.07b
L+329.67%
5,874,926,28215,684,592,5653,513,515,5237,487,122,7614,332,522,956000-9,257,899,14011,327,790,50018,396,771,47031,132,729,60012,895,226,00013,169,643,00064,412,966,00058,833,000,00034,620,000,000-12,350,681,000-53,067,000,000
CFO
18.88b
P
8,058,028,67417,293,805,9136,649,571,3109,418,937,1127,444,163,6623,373,177,3201,755,014,8107,242,238,0007,478,089,00010,519,698,00023,673,195,00024,947,266,00022,469,159,00013,560,922,00064,087,000,00066,398,000,00025,722,000,000-92,862,00018,879,000,000
Dividend
Jan 17, 202228 RUB/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Actavia Life Sciences, Inc. operates as a biotechnology enterprise specializing in the development of therapeutic solutions aimed at treating various forms of leukemia and lymphoma. Additionally, the company is engaged in formulating small molecule drug candidates, with a particular emphasis on addressing acute myeloid leukemia. Established in 2013, its corporate headquarters are situated in New York, NY.
URL
http://www.raspadskaya.ru/
IPO date
Nov 10, 2006
Employees
Domiciled in
RU
Incorporated in
RU

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT